A randomized, open, single center clinical trial of Orlistat in the treatment of nonalcoholic fatty liver disease

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-17012258

Enrollment

Unknown

Registered

2017-08-05

Start date

2017-09-01

Completion date

Unknown

Last updated

2017-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-alcoholic fatty liver disease

Interventions

treatment group:Orlistat 120mg, 3 times a day

control group:placebo 120mg, 3 times a day

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Clinically and pathologically diagnosed with NAFLD on the basis of Guidelines for the diagnosis and treatment of nonalcoholic fatty liver disease of China; 2. aged from 18~60 years; 3. BMI = 27.

Exclusion criteria

Exclusion criteria: 1. drug allergy history; 2. ALT = 120U/L; 3. accompanied with other liver diseases or end-stage liver diseases; 4. women in pregnancy or lactation; 5. accompanied with thyroid disease, diabetes, pancreatic disease, malabsorption syndrome, organic heart disease, respiratory diseases, hematological system diseases or kidney disease; 6. previous abdominal surgery; 7. have taken steatohepatitis treatments within 3 months; 8. have taken drugs for metabolic disorder; 9. have received transfusions within 3 months; 10. have taken steroid therapy within 6 months.

Design outcomes

Primary

Measure	Time frame
hepatic fat fraction;liver pathology;Hepatic fat quantification;liver stiffness;Haematological index;	—

Countries

China

Contacts

Public ContactBIHUI ZHONG

The First Affiliated Hospital of Sun Yat-sen University

sophiazhong@hotmail.com+86 020-87755766-8172

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 22, 2026